Citation Impact
Citing Papers
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
2010 Standout
Identification of a Primary Target of Thalidomide Teratogenicity
2010 StandoutScience
Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
2005 Standout
Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study
2011 Standout
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Urinary Albumin Excretion in Heart Failure with Preserved Ejection Fraction: An Interim Analysis of the CHART 2 Study
2012
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
2008 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma
2005
Treatment of kidney cancer
2009 StandoutNobel
FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis
2010 StandoutNobel
Cancer statistics, 2024
2024 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Molecular imaging in drug development
2008 Standout
The tor pathway: a target for cancer therapy
2004 Standout
Anti-angiogenic therapy: Rationale, challenges and clinical studies
2002
Oxidative stress, inflammation, and cancer: How are they linked?
2010 Standout
How many drug targets are there?
2006 Standout
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Effect of pegylation on pharmaceuticals
2003 Standout
Clinical uses of pegylated pharmaceuticals in oncology
2002
Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances
2007
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Medicinal mushroom modulators of molecular targets as cancer therapeutics
2005 Standout
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
Anti-angiogenic activity of inositol hexaphosphate (IP6)
2004
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions
2021
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
2005 Standout
Targeting the phosphoinositide 3-kinase pathway in cancer
2009 Standout
A structure-based computational workflow to predict liability and binding modes of small molecules to hERG
2020 StandoutNobel
Cancer genes and the pathways they control
2004 Standout
Polymer conjugates as anticancer nanomedicines
2006 Standout
Understanding the Importance of Smart Drugs in Renal Cell Carcinoma
2006
Molecular Pathways in Renal Cell Carcinoma—Rationale for Targeted Treatment
2006
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
2010
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Novel approaches in the therapy of metastatic renal cell carcinoma
2005
Blood Flow Changes in Hepatocellular Carcinoma After the Administration of Thalidomide Assessed by Reperfusion Kinetics During Microbubble Infusion
2005
Tumor delivery of macromolecular drugs based on the EPR effect
2010 Standout
Sickle-cell disease
2010 Standout
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
2007 Standout
Overview of the clinical efficacy of investigational anticancer drugs
2003
The tumor microenvironment and its role in promoting tumor growth
2008 Standout
Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
2016 Standout
Enzymatic procedure for site-specific pegylation of proteins
2002
Thalidomide
2004
Novel treatment strategies in clear-cell metastatic renal cell carcinoma
2005
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
2015 Standout
Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease
2013
Targeting Apoptosis Pathways in Cancer Therapy
2004
Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway
2008 StandoutNobel
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
Cancer-related inflammation
2008 StandoutNature
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
2006 Standout
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Modes of resistance to anti-angiogenic therapy
2008 Standout
Angiogenesis as a therapeutic target
2005 StandoutNature
Tumor Angiogenesis
2008 Standout
The dawning era of polymer therapeutics
2003 Standout
Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer
2004
General principles of tumor immunotherapy : basic and clinical applications of tumor immunology
2007
Vascular remodeling and clinical resistance to antiangiogenic cancer therapy
2004
Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer
2006
Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
2008
Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma
2004
The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development
2011
Thalidomide Pharmacokinetics and Metabolite Formation in Mice, Rabbits, and Multiple Myeloma Patients
2004
Biology and Clinical Development of Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell Carcinoma
2004
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
2007 Standout
Inositol Polyphosphate Multikinase Inhibits Angiogenesis via Inositol Pentakisphosphate-Induced HIF-1α Degradation
2017 StandoutNobel
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
2009 Standout
Cancer treatment and survivorship statistics, 2016
2016 Standout
Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference
2007 StandoutNobel
Cancer statistics, 2016
2016 Standout
Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions
2005
Cancer statistics, 2015
2015 Standout
Cancer treatment and survivorship statistics, 2019
2019 Standout
Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma
2004
Pegylated Interferon Alfa-2b Treatment for Patients With Solid Tumors: A Phase I/II Study
2002
Randomized Phase II Study of Erlotinib Combined With Bevacizumab Compared With Bevacizumab Alone in Metastatic Renal Cell Cancer
2007
Tumor Necrosis Factor α As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose
2007
RENAL CELL CARCINOMA 2005: NEW FRONTIERS IN STAGING, PROGNOSTICATION AND TARGETED MOLECULAR THERAPY
2005
Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
2004
Treatment Outcome and Survival Associated With Metastatic Renal Cell Carcinoma of Non–Clear-Cell Histology
2002
Treatments for chronic myeloid leukemia: a qualitative systematic review
2012
Works of Richard Yu being referenced
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)
2017
Phase II Trial of Irofulven (6-Hydroxymethylacylfulvene) for Patients with Advanced Renal Cell Carcinoma
2001
Diagnostic Accuracy of Urine Dipsticks for Detection of Albuminuria in the General Community
2011
Phase II Trial of Arsenic Trioxide in Patients with Metastatic Renal Cell Carcinoma
2002
Phase II Trial of Antiepidermal Growth Factor Receptor Antibody C225 in Patients with Advanced Renal Cell Carcinoma
2003
Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Newly Diagnosed Patients with AML.
2005
Phase II Trial of Thalidomide for Patients With Advanced Renal Cell Carcinoma
2002
Phase I Trial of 40-kd Branched Pegylated Interferon Alfa-2a for Patients With Advanced Renal Cell Carcinoma
2001
Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
2009